应用休克学术研究联盟(SHARC)共识定义描述心源性休克流行病学
本研究在CCCTN多国高级心脏重症监护室网络中,应用SHARC共识定义对2017—2023年符合休克标准的8974例患者进行心源性休克分类。在5869例心源性休克患者中,27%为急性心肌梗死相关(65%为STEMI),59%为心衰相关(72%为慢性心衰急性加重、28%为新发),14%为继发性。急性心肌梗死相关和新发心衰相关患者最常合并心脏骤停(P<0.001),急性心肌梗死相关和混合性休克最常表现为更严重休克分期(SCAI D或E;P<0.001)。住院死亡率以混合性休克最高(48%),其次为急性心肌梗死相关(41%),新发心衰相关和继发性均为31%,慢性心衰急性加重最低(25%;P<0.001)。
要点
- 在5869例心源性休克患者中,心衰相关占59%(其中72%为慢性心衰急性加重、28%为新发),急性心肌梗死相关占27%(65%为STEMI),继发性占14%。
- 混合性休克住院死亡率最高(48%),急性心肌梗死相关为41%,新发心衰相关和继发性均为31%,慢性心衰急性加重最低(25%;P<0.001)。
- 急性心肌梗死相关和混合性休克最常表现为更严重休克分期(SCAI D或E;P<0.001)。
- 急性心肌梗死相关和新发心衰相关患者最常合并心脏骤停(P<0.001)。
- 临时机械循环支持使用率在急性心肌梗死相关心源性休克中最高(59%)。
适用人群与场景
- CCCTN多国高级心脏重症监护室网络中的患者,2017—2023年符合休克标准者共8974例,其中心源性休克5869例。
- 心源性休克定义为心脏疾病导致收缩压<90 mmHg持续≥30分钟,或需血管升压药、正性肌力药或机械循环支持维持收缩压≥90 mmHg,并有低灌注证据。
- 排除心脏术后心源性休克;同时具有心源性和非心源性休克成分者单独归类为混合性休克。
诊断标准与关键阈值
- 心源性休克定义:心脏疾病导致收缩压<90 mmHg持续≥30分钟,或需血管升压药、正性肌力药或机械循环支持维持收缩压≥90 mmHg,并有低灌注证据。
- 病因分类:急性心肌梗死相关心源性休克、心衰相关心源性休克(再分为新发与慢性心衰急性加重)、非心肌性(继发性)心源性休克;混合性休克单独分类。
红旗征与不能漏的情况
- 急性心肌梗死相关和新发心衰相关心源性休克最常合并心脏骤停(P<0.001)。
- 急性心肌梗死相关和混合性休克最常表现为更严重休克分期(SCAI D或E;P<0.001)。
研究设计与关键结果
- 研究类型为CCCTN多国注册研究,2017—2023年共8974例符合休克标准,其中心源性休克5869例。
- 在8974例休克患者中,65%为孤立性心源性休克,17%为混合性休克。
- 心源性休克病因:急性心肌梗死相关27%(其中65%为STEMI),心衰相关59%(其中72%为慢性心衰急性加重、28%为新发),继发性14%。
- 住院死亡率:混合性休克48%,急性心肌梗死相关41%,新发心衰相关31%,继发性31%,慢性心衰急性加重25%(P<0.001)。
- 临时机械循环支持使用率在急性心肌梗死相关心源性休克中最高(59%)。
证据类型、等级与局限
- 证据类型:基于CCCTN多国注册研究(2017—2023年)的观察性流行病学分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- SHARC共识定义可在当代注册研究中实际应用,并揭示具有不同表型和结局的离散心源性休克亚群,可能对临床实践和未来研究有意义。
指南或共识出处
- Shock Academic Research Consortium(SHARC)共识定义;Critical Care Cardiology Trials Network(CCCTN)注册研究;发表于Eur Heart J Acute Cardiovasc Care。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
AIMS: The Shock Academic Research Consortium (SHARC) recently proposed pragmatic consensus definitions to standardize classification of cardiogenic shock (CS) in registries and clinical trials. We aimed to describe contemporary CS epidemiology using the SHARC definitions in a cardiac intensive care unit (CICU) population.
METHODS AND RESULTS: The Critical Care Cardiology Trials Network (CCCTN) is a multinational research network of advanced CICUs coordinated by the TIMI Study Group (Boston, MA). Cardiogenic shock was defined as a cardiac disorder resulting in SBP < 90 mmHg for ≥30 min [or the need for vasopressors, inotropes, or mechanical circulatory support (MCS) to maintain SBP ≥ 90 mmHg] with evidence of hypoperfusion. Primary aetiologic categories included acute myocardial infarction-related CS (AMI-CS), heart failure-related CS (HF-CS), and non-myocardial (secondary) CS. Post-cardiotomy CS was not included. Heart failure-related CS was further subcategorized as de novo vs. acute-on-chronic HF-CS. Patients with both cardiogenic and non-cardiogenic components of shock were classified separately as mixed CS. Of 8974 patients meeting shock criteria (2017-23), 65% had isolated CS and 17% had mixed shock. Among patients with CS (n = 5869), 27% had AMI-CS (65% STEMI), 59% HF-CS (72% acute-on-chronic, 28% de novo), and 14% secondary CS. Patients with AMI-CS and de novo HF-CS were most likely to have had concomitant cardiac arrest (P < 0.001). Patients with AMI-CS and mixed CS were most likely to present in more severe shock stages (SCAI D or E; P < 0.001). Temporary MCS use was highest in AMI-CS (59%). In-hospital mortality was highest in mixed CS (48%), followed by AMI-CS (41%), similar in de novo HF-CS (31%) and secondary CS (31%), and lowest in acute-on-chronic HF-CS (25%; P < 0.001).
CONCLUSION: SHARC consensus definitions for CS classification can be pragmatically applied in contemporary registries and reveal discrete subpopulations of CS with distinct phenotypes and outcomes that may be relevant to clinical practice and future research.
参考来源
- Berg DD, Bohula EA, Patel SM, et al. Epidemiology of cardiogenic shock using the Shock Academic Research Consortium (SHARC) consensus definitions. Eur Heart J Acute Cardiovasc Care. 2024. PMID: 39208447. doi:10.1093/ehjacc/zuae098
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。